Impact BioMedical
20 hedge funds and large institutions have $2.23M invested in Impact BioMedical in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 9 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
208% more capital invested
Capital invested by funds: $726K → $2.23M (+$1.51M)
18.73% more ownership
Funds ownership: 11.82% → 30.55% (+19%)
17% less funds holding
Funds holding: 24 → 20 (-4)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$559K |
| 2 |
State Street
Boston,
Massachusetts
|
+$298K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$117K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.1K |
| 5 |
GTAM
Global Trust Asset Management
West Palm Beach,
Florida
|
+$909 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$69.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$11.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.33K |
| 4 |
Jane Street
New York
|
-$7.11K |
| 5 |
HF
HRT Financial
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| – | -$720 | -1,426 | Closed |
|
27
Bank of America
Charlotte,
North Carolina
| – | -$467 | -924 | Closed |
|
|
SRCM
28
Signature Resources Capital Management
Newport Beach,
California
| – | -$2 | -4 | Closed |
|
29
Group One Trading
Chicago,
Illinois
| – | -$1 | -1 | Closed |
|
IBO Hedge Fund Activity: Q1 2026 in Review
20 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q1 2026, worth a combined $2.23M — up 208% from $726K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IBO and 6 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Geode Capital Management, adding an estimated $559K. The largest seller was Millennium Management, exiting entirely with an estimated $69.6K sold.
- 20 institutional investors held Impact BioMedical (IBO) as of Q1 2026, down from 24 in Q4 2025.
- Funds reported $2.23M of Impact BioMedical stock for Q1 2026, up 208% quarter-over-quarter.
- 6 funds opened new Impact BioMedical positions in Q1 2026 and 9 closed out, a net change of -3 holders.
- The largest Impact BioMedical buyer in Q1 2026 was Geode Capital Management, an estimated $559K added.
- The largest Impact BioMedical seller in Q1 2026 was Millennium Management, an estimated $69.6K sold.
Based on aggregated 13F filings for Q1 2026.